Abstract
Matthew J. Ahearne, Matthew A. Timmins, Charlotte Gaskell, Aimee E. Jackson, Clare M. Morland, Sonia Fox, Louise M. Hopkins, Nadia Nawaz, Susann Lehmann, Marc Wadsley, Caroline M. Cowley, Jacqueline Shaw, Naeem Khan, Nagesh Kalakonda, Christopher S. Trethewey, Ram Malladi, Paul A. Fields, Dima El‐Sharkawi, Michael Quinn, Nimish Shah, Andrew John Davies, Kim Linton, Pam McKay, Rod Johnson, Simon D. Wagner, David John Lewis, Graham P. Collins, Christopher Paul Fox, Kate Cwynarski
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
CHOP versus GEM‐P in previously untreated patients with peripheral T‐cell lymphoma (CHEMO‐T): a phase 2, multicentre, randomised, open‐label trial
10.1016/s2352-3026(18)30039-5 · 2018
Survival of patients with peripheral T‐cell lymphoma after first relapse or progression: spectrum of disease and rare long‐term survivors
10.1200/jco.2012.44.7524 · 2013
SHP‐1 and SHP‐2 associate with immunoreceptor tyrosine‐based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
10.4049/jimmunol.173.2.945 · 2004
Safety, activity, and immune correlates of anti‐PD‐1 antibody in cancer
10.1056/nejmoa1200690 · 2012
Safety and activity of anti‐PD‐L1 antibody in patients with advanced cancer
10.1056/nejmoa1200694 · 2012
PD‐1 regulates germinal center B cell survival and the formation and affinity of long‐lived plasma cells
10.1038/ni.1877 · 2010
PD‐1 controls follicular T helper cell positioning and function
10.1016/j.immuni.2018.06.012 · 2018
The receptor PD‐1 controls follicular regulatory T cells in the lymph nodes and blood
10.1038/ni.2496 · 2013
Bright PD‐1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T‐cell lymphoma
10.1038/s41408-020-0301-x · 2020
Germinal‐center T‐helper‐cell markers PD‐1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T‐cell lymphoma
10.1309/ajcp62wrkerpxdrt · 2009
Expression of follicular helper T cell markers in nodal peripheral T cell lymphomas: a tissue microarray analysis of 162 cases
10.1136/jcp.2010.084459 · 2011
Peripheral T‐cell lymphoma with follicular T‐cell markers
10.1097/pas.0b013e31817f123e · 2008
Treating relapsed/refractory mature T‐ and NK‐cell neoplasms with tislelizumab: a multicenter open‐label phase 2 study
10.1182/bloodadvances.2022009575 · 2023
Phase II study of the PD‐1 inhibitor Pembrolizumab for the treatment of relapsed or refractory mature T‐cell lymphoma
10.1016/j.clml.2019.03.022 · 2019
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open‐label phase 2 study (Gxplore‐002)
10.1186/s13045-021-01033-1 · 2021
Nivolumab in patients with relapsed or refractory peripheral T‐cell lymphoma: modest activity and cases of hyperprogression
10.1136/jitc-2022-004984 · 2022
B7‐H1 (PD‐L1, CD274) suppresses host immunity in T‐cell lymphoproliferative disorders
10.1182/blood-2009-04-216671 · 2009
Antibody‐dependent cellular cytotoxicity activity of a novel anti‐PD‐L1 antibody Avelumab (MSB0010718C) on human tumor cells
10.1158/2326-6066.cir-15-0059 · 2015
Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T‐cell lymphoma
10.1182/bloodadvances.2019001075 · 2020
CD38‐mediated immunosuppression as a mechanism of tumor cell escape from PD‐1/PD‐L1 blockade
10.1158/2159-8290.cd-17-1033 · 2018
Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T‐cell lymphomas
10.1073/pnas.1608839114 · 2017
PD‐1 is a haploinsufficient suppressor of T cell lymphomagenesis
10.1038/nature24649 · 2017
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T‐cell lymphoma (ORACLE): an open‐label randomised, phase 3 study
10.1016/s2352-3026(24)00102-9 · 2024
First‐line immunotherapy with anti‐PD‐1 antibody for extranodal NK/T‐cell lymphoma: a retrospective study
10.1111/bjh.18957 · 2023
Human inherited PD‐L1 deficiency is clinically and immunologically less severe than PD‐1 deficiency
2024
High‐dimensional and single‐cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL)
10.1038/s41375-021-01321-2 · 2022
Clinical predictive value of naïve and memory T cells in advanced NSCLC
10.3389/fimmu.2022.996348 · 2022
Integrated clinical and genomic evaluation of guadecitabine (SGI‐110) in peripheral T‐cell lymphoma
10.1038/s41375-022-01571-8 · 2022
Frontline chemoimmunotherapy with nivolumab and dose‐adjusted EPOCH in peripheral T‐cell lymphoma: a phase 1 trial
10.1182/bloodadvances.2023011526 · 2024
Whole‐genome CRISPR screening identifies molecular mechanisms of PD‐L1 expression in adult T‐cell leukemia/lymphoma
10.1182/blood.2023021423 · 2024
Whole‐genome CRISPR screening identifies molecular mechanisms of PD‐L1 expression in adult T‐cell leukemia/lymphoma
10.1182/blood.2023021423 · doi-reference
Frontline chemoimmunotherapy with nivolumab and dose‐adjusted EPOCH in peripheral T‐cell lymphoma: a phase 1 trial
10.1182/bloodadvances.2023011526 · doi-reference
Integrated clinical and genomic evaluation of guadecitabine (SGI‐110) in peripheral T‐cell lymphoma
10.1038/s41375-022-01571-8 · doi-reference
Clinical predictive value of naïve and memory T cells in advanced NSCLC
10.3389/fimmu.2022.996348 · doi-reference
High‐dimensional and single‐cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL)
10.1038/s41375-021-01321-2 · doi-reference
First‐line immunotherapy with anti‐PD‐1 antibody for extranodal NK/T‐cell lymphoma: a retrospective study
10.1111/bjh.18957 · doi-reference
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T‐cell lymphoma (ORACLE): an open‐label randomised, phase 3 study
10.1016/s2352-3026(24)00102-9 · doi-reference
PD‐1 is a haploinsufficient suppressor of T cell lymphomagenesis
10.1038/nature24649 · doi-reference
Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T‐cell lymphomas
10.1073/pnas.1608839114 · doi-reference
ror
Confidence 99%
europepmc
Confidence 96%
openalex
Confidence 95%
datacite
Confidence 0%
CD38‐mediated immunosuppression as a mechanism of tumor cell escape from PD‐1/PD‐L1 blockade
10.1158/2159-8290.cd-17-1033 · doi-reference
Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T‐cell lymphoma
10.1182/bloodadvances.2019001075 · doi-reference
Antibody‐dependent cellular cytotoxicity activity of a novel anti‐PD‐L1 antibody Avelumab (MSB0010718C) on human tumor cells
10.1158/2326-6066.cir-15-0059 · doi-reference
B7‐H1 (PD‐L1, CD274) suppresses host immunity in T‐cell lymphoproliferative disorders
10.1182/blood-2009-04-216671 · doi-reference
Nivolumab in patients with relapsed or refractory peripheral T‐cell lymphoma: modest activity and cases of hyperprogression
10.1136/jitc-2022-004984 · doi-reference
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open‐label phase 2 study (Gxplore‐002)
10.1186/s13045-021-01033-1 · doi-reference
Phase II study of the PD‐1 inhibitor Pembrolizumab for the treatment of relapsed or refractory mature T‐cell lymphoma
10.1016/j.clml.2019.03.022 · doi-reference
Treating relapsed/refractory mature T‐ and NK‐cell neoplasms with tislelizumab: a multicenter open‐label phase 2 study
10.1182/bloodadvances.2022009575 · doi-reference
Peripheral T‐cell lymphoma with follicular T‐cell markers
10.1097/pas.0b013e31817f123e · doi-reference
Expression of follicular helper T cell markers in nodal peripheral T cell lymphomas: a tissue microarray analysis of 162 cases
10.1136/jcp.2010.084459 · doi-reference
Germinal‐center T‐helper‐cell markers PD‐1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T‐cell lymphoma
10.1309/ajcp62wrkerpxdrt · doi-reference
Bright PD‐1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T‐cell lymphoma
10.1038/s41408-020-0301-x · doi-reference
The receptor PD‐1 controls follicular regulatory T cells in the lymph nodes and blood
10.1038/ni.2496 · doi-reference
PD‐1 controls follicular T helper cell positioning and function
10.1016/j.immuni.2018.06.012 · doi-reference
PD‐1 regulates germinal center B cell survival and the formation and affinity of long‐lived plasma cells
10.1038/ni.1877 · doi-reference
Safety and activity of anti‐PD‐L1 antibody in patients with advanced cancer
10.1056/nejmoa1200694 · doi-reference
Safety, activity, and immune correlates of anti‐PD‐1 antibody in cancer
10.1056/nejmoa1200690 · doi-reference
SHP‐1 and SHP‐2 associate with immunoreceptor tyrosine‐based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
10.4049/jimmunol.173.2.945 · doi-reference
Survival of patients with peripheral T‐cell lymphoma after first relapse or progression: spectrum of disease and rare long‐term survivors
10.1200/jco.2012.44.7524 · doi-reference
CHOP versus GEM‐P in previously untreated patients with peripheral T‐cell lymphoma (CHEMO‐T): a phase 2, multicentre, randomised, open‐label trial
10.1016/s2352-3026(18)30039-5 · doi-reference